CN106661042A - 抗病毒化合物的固体形式 - Google Patents

抗病毒化合物的固体形式 Download PDF

Info

Publication number
CN106661042A
CN106661042A CN201580031460.3A CN201580031460A CN106661042A CN 106661042 A CN106661042 A CN 106661042A CN 201580031460 A CN201580031460 A CN 201580031460A CN 106661042 A CN106661042 A CN 106661042A
Authority
CN
China
Prior art keywords
compound
bis
imidazol
phosphate
salt form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580031460.3A
Other languages
English (en)
Chinese (zh)
Inventor
O·V·拉皮纳
石兵
王芳
S·A·沃尔肯豪尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Pharmasset LLC
Original Assignee
Pharmasset Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Inc filed Critical Pharmasset Inc
Publication of CN106661042A publication Critical patent/CN106661042A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201580031460.3A 2014-06-11 2015-06-08 抗病毒化合物的固体形式 Pending CN106661042A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010919P 2014-06-11 2014-06-11
US62/010,919 2014-06-11
PCT/US2015/034649 WO2015191431A1 (en) 2014-06-11 2015-06-08 Solid forms of an antiviral compound

Publications (1)

Publication Number Publication Date
CN106661042A true CN106661042A (zh) 2017-05-10

Family

ID=53443009

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580031460.3A Pending CN106661042A (zh) 2014-06-11 2015-06-08 抗病毒化合物的固体形式

Country Status (19)

Country Link
US (4) US9630972B2 (https=)
EP (3) EP3822275A1 (https=)
JP (3) JP2017517532A (https=)
KR (3) KR20190007533A (https=)
CN (1) CN106661042A (https=)
AR (1) AR103194A1 (https=)
AU (2) AU2015274961A1 (https=)
BR (1) BR112016028843A2 (https=)
CA (1) CA2951188C (https=)
EA (1) EA201692220A1 (https=)
ES (1) ES2785409T3 (https=)
IL (1) IL249041A0 (https=)
MX (1) MX2016016299A (https=)
PL (1) PL3154983T3 (https=)
PT (1) PT3154983T (https=)
SG (1) SG11201609810YA (https=)
SI (1) SI3154983T1 (https=)
TW (1) TWI721947B (https=)
WO (1) WO2015191431A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
SI2640719T1 (sl) 2010-11-17 2017-07-31 Gilead Pharmasset Llc Antivirusne spojine
JP6082749B2 (ja) 2011-11-16 2017-02-15 ギリアド ファーマセット エルエルシー 抗ウイルス化合物としての縮合イミダゾリルイミダゾール
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
JOP20170127A1 (ar) 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
CN106432253B (zh) * 2016-09-21 2019-06-14 上海众强药业有限公司 一种维帕他韦新晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328480A (zh) * 2011-11-16 2013-09-25 吉利德科学公司 作为抗病毒化合物的缩合的咪唑基咪唑
WO2013173488A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds inhibitors of hcv ns5b

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JPWO2004089933A1 (ja) * 2003-04-02 2006-07-06 アステラス製薬株式会社 フルオロベンズアミド誘導体の新規結晶
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
EP1799685B1 (en) * 2004-09-22 2012-03-28 Pfizer Inc. Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
AU2007248282B2 (en) 2006-05-05 2011-12-08 Merck Patent Gmbh Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2009286694A (ja) * 2006-09-07 2009-12-10 Eisai R & D Management Co Ltd ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶
CA2823981C (en) 2006-12-07 2016-05-17 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5282037B2 (ja) * 2007-08-10 2013-09-04 田辺三菱製薬株式会社 新規なイソキノリン化合物の塩及びその結晶
ATE551337T1 (de) 2008-02-12 2012-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
HRP20120706T1 (hr) 2008-02-13 2012-09-30 Bristol-Myers Squibb Company Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2732777A1 (en) 2008-08-07 2010-02-11 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
SI2373172T1 (sl) 2008-12-03 2013-12-31 Presidio Pharmaceuticals, Inc. Inhibitorji HCV NS5A
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
SG174883A1 (en) 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
SG174929A1 (en) 2009-03-27 2011-11-28 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
WO2010132538A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
PT3309157T (pt) 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201290089A1 (ru) 2009-09-04 2012-09-28 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Химические соединения
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
SG188618A1 (en) 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
SI2640719T1 (sl) 2010-11-17 2017-07-31 Gilead Pharmasset Llc Antivirusne spojine
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
HK1201186A1 (en) 2011-12-29 2015-08-28 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
TW201434949A (zh) 2013-01-31 2014-09-16 Nitto Denko Corp 環氧組合物及環氧樹脂成形體
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置
EP3588013A1 (de) 2018-06-26 2020-01-01 XelectriX Power GmbH Verfahren zur abgabe von elektrischer energie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328480A (zh) * 2011-11-16 2013-09-25 吉利德科学公司 作为抗病毒化合物的缩合的咪唑基咪唑
WO2013173488A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds inhibitors of hcv ns5b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MINO R. CAIRA: "Crystalline Polymorphism of Organic Compounds", 《TOPICS IN CURRENT CHEMISTRY》 *
RICHARD J. BASTIN，等: "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》 *

Also Published As

Publication number Publication date
JP2017517532A (ja) 2017-06-29
IL249041A0 (en) 2017-01-31
CA2951188A1 (en) 2015-12-17
US9630972B2 (en) 2017-04-25
US20170247386A1 (en) 2017-08-31
SI3154983T1 (sl) 2020-04-30
EA201692220A1 (ru) 2017-05-31
AU2018201948A1 (en) 2018-04-12
ES2785409T3 (es) 2020-10-06
TW201609745A (zh) 2016-03-16
SG11201609810YA (en) 2016-12-29
AR103194A1 (es) 2017-04-26
US11203599B2 (en) 2021-12-21
MX2016016299A (es) 2017-04-06
KR20190007533A (ko) 2019-01-22
US20190270750A1 (en) 2019-09-05
EP3154983A1 (en) 2017-04-19
BR112016028843A2 (pt) 2017-08-22
KR20200145852A (ko) 2020-12-30
CA2951188C (en) 2019-09-24
JP2019172711A (ja) 2019-10-10
EP3666775A1 (en) 2020-06-17
EP3154983B1 (en) 2020-02-12
US20200283449A1 (en) 2020-09-10
US10604530B2 (en) 2020-03-31
PL3154983T3 (pl) 2020-06-29
US20150361085A1 (en) 2015-12-17
KR20170015506A (ko) 2017-02-08
EP3822275A1 (en) 2021-05-19
PT3154983T (pt) 2020-05-06
AU2018201948B2 (en) 2019-10-03
JP2019070057A (ja) 2019-05-09
TWI721947B (zh) 2021-03-21
AU2015274961A1 (en) 2016-12-01
WO2015191431A1 (en) 2015-12-17
US9884873B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
CN106661042A (zh) 抗病毒化合物的固体形式
JP7675777B2 (ja) 免疫調節剤としての複素環式化合物
CN110636884B (zh) 新结晶形式
JP6471103B2 (ja) ヒスタミンｈ４受容体のベンゾイミダゾール−２−イルピリミジンモジュレータ
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
BR112021004094A2 (pt) formas cristalinas de um inibidor de fosfoinositídeo 3-quinase (pi3k)
HK1237346A1 (en) Solid forms of an antiviral compound
HK40031882A (en) Solid forms of an antiviral compound
HK1236199B (en) Solid forms of an antiviral compound
HK1236199A1 (en) Solid forms of an antiviral compound
TW202327593A (zh) Kras抑制劑的多晶型物及其製備方法和用途
WO2026064643A1 (en) Compounds, compositions, and methods of use thereof
WO2026017041A1 (zh) 一种吡唑并喹唑啉类化合物及其盐型和晶型
HK40110051A (zh) 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法
HK40047182B (en) Heterocyclic compounds as immunomodulators
HK40047182A (en) Heterocyclic compounds as immunomodulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237346

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170510

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1237346

Country of ref document: HK